https://www.selleckchem.com/pr....oducts/monocrotaline
Technical success was achieved in all cases. Adverse events were border-line significantly more common in the Group 4/7 (57%) (pain n=3; pain and rectal bleeding n=1) compared with the Group 0/5 (0%), p=0.08, which resulted in preterm termination of the study. The clinical success rate was Group 6/7 (86%) vs Group 1/5 (20%), p=0.07. Patients with strictures related to Crohn's disease may benefit from treatment with self-expandable metal stents rather than dilatation. However, there seems to be an increased risk for patient pain af
Like
Comment
Share
